Vicki P Hoffmann

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study
    Vicki Poole Hoffmann
    Neuroscience Division, Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychiatry 73:216-23. 2012
  2. pmc Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Virginia L Stauffer
    Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:89. 2010
  3. pmc Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
    Ilya Lipkovich
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 8:78. 2008
  4. ncbi request reprint Wellness intervention for patients with serious and persistent mental illness
    Vicki Poole Hoffmann
    From Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Clin Psychiatry 66:1576-9. 2005
  5. ncbi request reprint Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
    Vicki P Hoffmann
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:656-60. 2010
  6. doi request reprint Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women
    John Houston
    Lilly USA LLC, Indianapolis, IN, USA
    Psychiatry Res 187:74-9. 2011
  7. pmc The potential role of appetite in predicting weight changes during treatment with olanzapine
    Michael Case
    Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 10:72. 2010
  8. doi request reprint Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study
    Tamas Treuer
    Neuroscience Research, Lilly Hungaria Kft, Budapest, Hungary
    World J Biol Psychiatry 10:729-40. 2009
  9. pmc Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
    Virginia L Stauffer
    Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
    BMC Psychiatry 9:12. 2009
  10. doi request reprint Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
    Jamie Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Hum Psychopharmacol 23:275-81. 2008

Detail Information

Publications14

  1. doi request reprint Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study
    Vicki Poole Hoffmann
    Neuroscience Division, Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychiatry 73:216-23. 2012
    ....
  2. pmc Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Virginia L Stauffer
    Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:89. 2010
    ..To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent...
  3. pmc Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
    Ilya Lipkovich
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 8:78. 2008
    ..We therefore conducted a post-hoc analysis of clinical trial data, examining early weight gain as a predictor of later substantial weight gain...
  4. ncbi request reprint Wellness intervention for patients with serious and persistent mental illness
    Vicki Poole Hoffmann
    From Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Clin Psychiatry 66:1576-9. 2005
    ..Obesity is difficult to reverse, but behavioral programs involving diet and exercise are sometimes successful...
  5. ncbi request reprint Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
    Vicki P Hoffmann
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:656-60. 2010
    ..Clinical monitoring is advised throughout treatment for all patients...
  6. doi request reprint Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women
    John Houston
    Lilly USA LLC, Indianapolis, IN, USA
    Psychiatry Res 187:74-9. 2011
    ..Five of these SNPs fall in or are adjacent to an LD block spanning DRD2 intron 7, exon 7, 5' untranslated region and ANKK1. Clinical trial Registration: www.clinicaltrial.gov...
  7. pmc The potential role of appetite in predicting weight changes during treatment with olanzapine
    Michael Case
    Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 10:72. 2010
    ..Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite...
  8. doi request reprint Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study
    Tamas Treuer
    Neuroscience Research, Lilly Hungaria Kft, Budapest, Hungary
    World J Biol Psychiatry 10:729-40. 2009
    ..These results indicate that the influence of environmental, eating- and lifestyle-related factors should be considered when assessing weight gain during olanzapine therapy...
  9. pmc Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
    Virginia L Stauffer
    Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
    BMC Psychiatry 9:12. 2009
    ..Identification of patient subgroups with different degrees of susceptibility to the effect of weight mitigating agents during olanzapine treatment may aid clinicians in treatment decisions...
  10. doi request reprint Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
    Jamie Karagianis
    Clinical Research, Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Hum Psychopharmacol 23:275-81. 2008
    ..The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine...
  11. ncbi request reprint Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States
    Peter D Feldman
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Med Dir Assoc 5:38-46. 2004
    ..The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications...
  12. ncbi request reprint Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials
    Joseph L Micca
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Geriatr Psychiatry 14:62-70. 2006
    ..The objective of this study was to evaluate the association of established risk factors for treatment-emergent diabetes (TED) among patients over 65 years of age with dementia who received treatment with olanzapine...
  13. ncbi request reprint Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics
    Leslie L Citrome
    Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
    Ann Pharmacother 41:1593-603. 2007
    ..Type 2 diabetes mellitus has been reported during antipsychotic treatment...
  14. ncbi request reprint What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics?
    Jamie Karagianis
    J Clin Psychiatry 68:799-800; author reply 801-2. 2007